Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalassemia intermedia: revisited.

Ali Taher1, Hussain Isma'eel, Maria D Cappellini

  • 1Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon. ataher@aub.edu.lb

Blood Cells, Molecules & Diseases
|June 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EHA Recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies.

HemaSphere·2026
Same author

Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermedia.

Blood advances·2026
Same author

How I manage luspatercept in transfusion-dependent beta-thalassemia.

HemaSphere·2026
Same author

Thalassaemia clinical trials in war-stricken Lebanon: a story of struggle and resilience.

The Lancet. Haematology·2026
Same author

Spirituality and cancer: quality of life, anxiety/depression and symptom severity.

BMJ supportive & palliative care·2025
Same author

Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a study.

Orphanet journal of rare diseases·2025

Thalassemia intermedia presents a broad range of symptoms and complications, often requiring management strategies distinct from thalassemia major. This review examines these complications and proposes therapeutic approaches for better patient outcomes.

Area of Science:

  • Hematology
  • Genetics
  • Internal Medicine

Background:

  • Thalassemia intermedia (TI) exhibits a wide clinical spectrum, with varying onset and severity.
  • TI patients may develop unique complications like extramedullary hematopoiesis, leg ulcers, gallstones, and thrombophilia, which are less common in thalassemia major.
  • Current management often involves infrequent or no blood transfusions, with a focus on managing hemoglobin levels between 7-9 g/dl and iron overload.

Purpose of the Study:

  • To review the major clinical complications associated with thalassemia intermedia.
  • To suggest therapeutic strategies for preventing and managing these complications.
  • To address the lack of clear transfusion guidelines for TI patients.

Main Methods:

  • Review of clinical complications in thalassemia intermedia.

Related Experiment Videos

  • Analysis of retrospective clinical observations.
  • Literature review on TI management.

    • Main Results:

    • Thalassemia intermedia patients face a spectrum of complications, including extramedullary hematopoiesis, leg ulcers, gallstones, and thrombophilia.
    • The decision for blood transfusion therapy in TI is complex, balancing transfusion benefits against iron overload risks.
    • Existing guidelines for transfusion initiation and maintenance in TI are lacking.

    Conclusions:

    • Effective management of TI complications requires tailored strategies, considering the heterogeneity of the disease.
    • Further research and clear guidelines are needed for optimal transfusion and chelation therapy in thalassemia intermedia.
    • Addressing TI-specific complications is crucial for improving patient quality of life.